Next Article in Journal
Specific Antibodies and Arachidonic Acid Mediate the Protection Induced by the Schistosoma mansoni Cysteine Peptidase-Based Vaccine in Mice
Next Article in Special Issue
Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide
Previous Article in Journal
Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats
Previous Article in Special Issue
CD4+ T Cells Induced by Tuberculosis Subunit Vaccine H1 Can Improve the HIV-1 Env Humoral Response by Intrastructural Help
Article

Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers

1
Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, P.O. Box 65001 Dar es Salaam, Tanzania
2
Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, 17177 Stockholm, Sweden
3
The US Military HIV Research Program, The Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA
4
United States Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
5
Department of Internal Medicine, Muhimbili University of Health and Allied Sciences, P.O. Box 65001 Dar es Salaam, Tanzania
6
Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA
7
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 17177 Stockholm, Sweden
8
Venhälsan, Karolinska Institutet at Södersjukhuset, 11883 Stockholm, Sweden
9
Department of Microbiology, Public Health Agency of Sweden, 17182 Solna, Sweden
10
Department of Global Public Health, Karolinska Institutet, 17177 Stockholm, Sweden
*
Author to whom correspondence should be addressed.
Current address: Department of Immunology, Graduate Program in Microbiology and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Current address: College of Health and Allied Sciences, Boko Campus, St Joseph University in Tanzania, Kinondoni, P.O. Box 11007 Dar es Salaam, Tanzania.
Vaccines 2020, 8(4), 681; https://doi.org/10.3390/vaccines8040681
Received: 6 October 2020 / Revised: 9 November 2020 / Accepted: 11 November 2020 / Published: 13 November 2020
(This article belongs to the Special Issue HIV Vaccine)
We evaluated antibody responses to the human immunodeficiency virus (HIV) envelope variable regions 1 and 2 (V1V2) in 29 vaccinees who had received three HIV-1 DNA immunizations and two HIV-modified vaccinia virus Ankara (MVA) boosts in the phase I/II HIVIS03 vaccine trial. Twenty vaccinees received a third HIV-MVA boost after three years in the HIVIS06 trial. IgG and IgG antibody subclasses to gp70V1V2 proteins of HIV-1 A244, CN54, Consensus C, and Case A2 were analysed using an enzyme-linked immunosorbent assay (ELISA). Cyclic V2 peptides of A244, Consensus C, and MN were used in a surface plasmon resonance (SPR) assay. Four weeks after the second HIV-MVA, anti-V1V2 IgG antibodies to A244 were detected in 97% of HIVIS03 vaccinees, in 75% three years later, and in 95% after the third HIV-MVA. Anti-CN54 V1V2 IgG was detectable in 48% four weeks after the second HIV-MVA. The SPR data supported the findings. The IgG response was predominantly IgG1. Four weeks after the second HIV-MVA, 85% of vaccinees had IgG1 antibodies to V1V2 A244, which persisted in 25% for three-years. IgG3 and IgG4 antibodies to V1V2 A244 were rare. In conclusion, the HIV-DNA/MVA vaccine regimen induced durable V1V2 IgG antibody responses in a high proportion of vaccinees. View Full-Text
Keywords: HIV; vaccine; DNA; MVA; V1V2 antibodies HIV; vaccine; DNA; MVA; V1V2 antibodies
Show Figures

Figure 1

MDPI and ACS Style

Joachim, A.; Msafiri, F.; Onkar, S.; Munseri, P.; Aboud, S.; Lyamuya, E.F.; Bakari, M.; Billings, E.; Robb, M.L.; Wahren, B.; Mhalu, F.S.; Sandström, E.; Rao, M.; Nilsson, C.; Biberfeld, G. Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers. Vaccines 2020, 8, 681. https://doi.org/10.3390/vaccines8040681

AMA Style

Joachim A, Msafiri F, Onkar S, Munseri P, Aboud S, Lyamuya EF, Bakari M, Billings E, Robb ML, Wahren B, Mhalu FS, Sandström E, Rao M, Nilsson C, Biberfeld G. Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers. Vaccines. 2020; 8(4):681. https://doi.org/10.3390/vaccines8040681

Chicago/Turabian Style

Joachim, Agricola, Frank Msafiri, Sayali Onkar, Patricia Munseri, Said Aboud, Eligius F. Lyamuya, Muhammad Bakari, Erik Billings, Merlin L. Robb, Britta Wahren, Fred S. Mhalu, Eric Sandström, Mangala Rao, Charlotta Nilsson, and Gunnel Biberfeld. 2020. "Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers" Vaccines 8, no. 4: 681. https://doi.org/10.3390/vaccines8040681

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop